Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects-Reference-Cited by-同舟云学术

Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects

Published:2017-04-11 Issue:8 Volume:60 Page:3252-3265
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wada Yasuhiro¹^ORCID,Nakano Seiji¹,Morimoto Akifumi¹,Kasahara Ken-ichi¹,Hayashi Takahiko¹,Takada Yoshio¹,Suzuki Hiroko¹,Niwa-Sakai Michiko¹,Ohashi Shigeki¹,Mori Mutsuhiro¹,Hirokawa Takatsugu²³,Shuto Satoshi^ORCID

Affiliation:

1. Pharmaceutical Research Center, Asahi Kasei Pharma Corporation, 632-1, Mifuku, Izunokuni, Shizuoka 410-2321, Japan

2. Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan

3. Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

Funder

Japan Agency for Medical Research and Development

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01197

Reference59 articles.

1. Differentiation of Receptor Systems activated by Sympathomimetic Amines

2. Molecular Characterization of the Human β 3 -Adrenergic Receptor